$Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration$

Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration

Background Uterine leiomyosarcoma (uLMS) responds poorly to conventional chemotherapeutic agents, and personalized therapies have yet to be systematically explored. Comprehensive genomic profiling (CGP) can identify therapeutic targets and provide insight into the biology of this highly aggressive t...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The oncologist (Dayton, Ohio) Ohio), 2017-04, Vol.22 (4), p.416-421
Hauptverfasser:	Elvin, Julia A., Gay, Laurie M., Ort, Rita, Shuluk, Joseph, Long, Jennifer, Shelley, Lauren, Lee, Ronald, Chalmers, Zachary R., Frampton, Garrett M., Ali, Siraj M., Schrock, Alexa B., Miller, Vincent A., Stephens, Philip J., Ross, Jeffrey S., Frank, Richard
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over CDKN2A Comprehensive genomic profiling Cyclin-Dependent Kinase Inhibitor p18 - genetics Female Gene Expression Regulation, Neoplastic - drug effects Genomics Gynecologic Oncology High-Throughput Nucleotide Sequencing - methods Humans Leiomyosarcoma - drug therapy Leiomyosarcoma - genetics Leiomyosarcoma - pathology Middle Aged Molecular Targeted Therapy Palbociclib Piperazines - administration & dosage Precision medicine Pyridines - administration & dosage Targeted therapy Uterine leiomyosarcoma Uterine Neoplasms - drug therapy Uterine Neoplasms - genetics Uterine Neoplasms - pathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!